{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T08:57:56Z","timestamp":1791622676622,"version":"4.3.4"},"reference-count":27,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pharmacologic targeting of the menin-KMT2A protein\u2013protein interaction has emerged as a therapeutic breakthrough for acute leukemias harboring KMT2A rearrangements or NPM1 mutations. The first-in-class menin inhibitor (revumenib) achieved accelerated regulatory approval in November 2024 for monotherapy of relapsed\/refractory KMT2A rearranged leukemia. Next-generation agents (ziftomenib, bleximenib, enzomenib, BMF-219) have displayed similar composite complete remission rates (20-35%) and overall response rates (45-65%) in heavily pretreated KMT2Ar and NPM1m acute myeloid leukemia (AML) with measurable residual disease (MRD) negativity and prolonged overall survival (5\u20137 months). While all menin inhibitors result in on-target blast differentiation with clinical sequelae (\u201cdifferentiation syndrome\u201d) in 10% to 20% of patients, not all menin inhibitors are the same, with differing safety, toxicity (heartrate corrected QT interval (QTc) prolongation, cytopenias), and pharmacokinetic profiles. Acquired mutations in the menin gene described in 39% of post-revumenib relapses have not been identified following other inhibitors (ziftomenib, bleximenib), prompting new questions about resistance mechanisms. These promising results swiftly led to the launch of multiple trials of menin inhibitors combined with intensive (cytarabine and anthracycline) and nonintensive (venetoclax and hypomethylating) chemotherapy backbones. To date, these triplets have yielded high response rates (ie, \u226580% in de novo, 50-70% in relapsed) with most patients achieving MRD negativity and prolonged one-year survival. Ongoing\/pending phase 3 trials will clarify whether menin blockade should be incorporated into frontline and maintenance regimens for all patients with KMT2A rearranged or NPM1 mutant disease. In the current era, menin inhibition remains a key pillar of the success of precision medicine for AML therapy.<\/jats:p>","DOI":"10.1182\/hematology.2025000755","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:10:09Z","timestamp":1764943809000},"page":"599-606","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":14,"title":["The promise of menin inhibitors: from approval to triplet regimens"],"prefix":"10.1182","volume":"2025","author":[{"given":"Rahul K.","family":"Thakur","sequence":"first","affiliation":[{"name":"Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice S.","family":"Wang","sequence":"additional","affiliation":[{"name":"Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"10393","key":"2025120616350555200_hem2025000755C1","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","article-title":"Acute myeloid leukaemia","volume":"401","author":"DiNardo","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"2025120616350555200_hem2025000755C2","doi-asserted-by":"crossref","first-page":"e35834","DOI":"10.1002\/cncr.35834","article-title":"Top advances of the year: acute myeloid leukemia","volume":"131","author":"Thakur","year":"2025","journal-title":"Cancer"},{"issue":"9","key":"2025120616350555200_hem2025000755C3","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1038\/s41375-021-01309-y","article-title":"Therapeutic implications of menin inhibition in acute leukemias","volume":"35","author":"Issa","year":"2021","journal-title":"Leukemia"},{"key":"2025120616350555200_hem2025000755C4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fped.2017.00004","article-title":"MLL-rearranged leukemias-an update on science and clinical approaches","volume":"5","author":"Winters","year":"2017","journal-title":"Front Pediatr"},{"issue":"7","key":"2025120616350555200_hem2025000755C5","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1158\/1538-7445.AM2023-3457","article-title":"Abstract 3457: characterization of acquired resistance mutations to menin inhibitors","volume":"83","author":"Perner","year":"2023","journal-title":"Cancer Res"},{"issue":"7954","key":"2025120616350555200_hem2025000755C6","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A- rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"issue":"10","key":"2025120616350555200_hem2025000755C7","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","article-title":"Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial","volume":"25","author":"Wang","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"2025120616350555200_hem2025000755C8","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1182\/blood-2024-207106","article-title":"Bleximenib dose optimization and determination of RP2D from a phase 1 study in relapsed\/refractory acute leukemia patients with KMT2A and NPM1 alterations","volume":"144","author":"Searle","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2025120616350555200_hem2025000755C9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1182\/blood-2024-194827","article-title":"Phase 1 results: first-in-human phase 1\/2 study of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia","volume":"144","author":"Zeidner","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2025120616350555200_hem2025000755C10","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1182\/blood-2023-173149","article-title":"Covalent menin inhibitor Bmf-219 in patients with relapsed or refractory (R\/R) acute leukemia (AL): preliminary phase 1 data from the covalent-101 study","volume":"142","author":"Lancet","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2025120616350555200_hem2025000755C11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J Clin Oncol"},{"issue":"9","key":"2025120616350555200_hem2025000755C12","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1182\/blood.2025028357","article-title":"Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study","volume":"146","author":"Arellano","year":"2025","journal-title":"Blood"},{"issue":"16","key":"2025120616350555200_hem2025000755C13","doi-asserted-by":"crossref","first-page":"6506","DOI":"10.1200\/JCO.2025.43.16_suppl.6506","article-title":"Ziftomenib in relapsed\/refractory (R\/R) NPM1-mutant acute myeloid leukemia (AML): phase 1b\/2 clinical activity and safety results from the pivotal KOMET-001 study","volume":"43","author":"Wang","year":"2025","journal-title":"J Clin Oncol"},{"key":"2025120616350555200_hem2025000755C14","article-title":"Safety and activity of revumenib in combination with fludarabine\/cytarabine (FLA) in patients with relapsed\/refractory acute leukemias","author":"Shukla","year":"2024"},{"issue":"1","key":"2025120616350555200_hem2025000755C15","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1182\/blood-2024-204375","article-title":"Phase I\/II study of the all-oral combination of revumenib (SNDX-5613) with decitabine\/cedazuridine (ASTX727) and venetoclax (SAVE) in R\/R AML","volume":"144","author":"Issa","year":"2024","journal-title":"Blood"},{"key":"2025120616350555200_hem2025000755C16","article-title":"Phase 1B study of azacitidine, venetoclax and revumenib in newly diagnosed older adults with NPM1 mutated or KMT2A rearranged AML: interim results of dose escalation from the BEAT AML consortium","author":"Zeidner","year":"2024"},{"issue":"1","key":"2025120616350555200_hem2025000755C17","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1182\/blood-2024-198218","article-title":"Ziftomenib combined with intensive induction (7\u200a+\u200a3) in newly diagnosed NPM1-m or KMT2A-r acute myeloid leukemia: interim phase 1a results from KOMET-007","volume":"144","author":"Zeidan","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2025120616350555200_hem2025000755C18","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1182\/blood-2024-199170","article-title":"Ziftomenib combined with venetoclax and azacitidine in R\/R NPM1 mutant or KMT2a-r acute myeloid leukemia: interim phase 1a results from KOMET-007","author":"Fathi","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2025120616350555200_hem2025000755C19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2024-207072","article-title":"Phase 1b study of menin-KMT2A inhibitor bleximenib in combination with intensive chemotherapy in newly diagnosed acute myeloid leukemia with KMT2Ar or NPM1 alterations","volume":"144","author":"Recher","year":"2024","journal-title":"Blood"},{"issue":"7954","key":"2025120616350555200_hem2025000755C20","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","article-title":"MEN1 mutations mediate clinical resistance to menin inhibition","volume":"615","author":"Perner","year":"2023","journal-title":"Nature"},{"issue":"19","key":"2025120616350555200_hem2025000755C21","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood.2023023644","article-title":"Epigenetic regulation of noncanonical menin targets modulates menin inhibitor response in acute myeloid leukemia","volume":"144","author":"Zhou","year":"2024","journal-title":"Blood"},{"issue":"10","key":"2025120616350555200_hem2025000755C22","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1158\/2159-8290.CD-24-1517","article-title":"Catalytic inhibition of KAT6\/KAT7 enhances the efficacy and overcomes primary and acquired resistance to menin inhibitors in MLL leukemia","volume":"15","author":"Gordon","year":"2025","journal-title":"Cancer Discov"},{"issue":"1","key":"2025120616350555200_hem2025000755C23","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1182\/blood-2024-202042","article-title":"Discovery of BTC-86, a novel second-generation menin-MLL inhibitor to overcome the acquired resistance in MEN1 for R\/R acute leukemia","volume":"144","author":"Liu","year":"2024","journal-title":"Blood"},{"issue":"20","key":"2025120616350555200_hem2025000755C24","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1182\/blood.2023022832","article-title":"BRG1\/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor","volume":"143","author":"Fiskus","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2025120616350555200_hem2025000755C25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-023-00826-6","article-title":"Targeting of epigenetic co-dependencies enhances anti-AML efficacy of menin inhibitor in AML with MLL1-r or mutant NPM1","volume":"13","author":"Fiskus","year":"2023","journal-title":"Blood Cancer J"},{"issue":"1","key":"2025120616350555200_hem2025000755C26","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2159-8290.CD-22-0416","article-title":"A molecular switch between mammalian MLL complexes dictates response to menin-MLL inhibition","volume":"13","author":"Soto-Feliciano","year":"2023","journal-title":"Cancer Discov"},{"issue":"8","key":"2025120616350555200_hem2025000755C27","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1038\/s41375-024-02312-9","article-title":"Combination of menin and kinase inhibitors as an effective treatment for leukemia with NUP98 translocations","volume":"38","author":"Miao","year":"2024","journal-title":"Leukemia"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/599\/2469812\/599thakur.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/599\/2469812\/599thakur.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T21:35:16Z","timestamp":1765056916000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2025\/1\/599\/556855\/The-promise-of-menin-inhibitors-from-approval-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,5]]},"published-print":{"date-parts":[[2025,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2025000755","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,5]]},"published":{"date-parts":[[2025,12,5]]}}}